Endothelial dysfunction associated with drug-eluting stents what, where, when, and how?
Joseph B
JB
Muhlestein
D000818:Animals; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D045462:Endothelium-Dependent Relaxing Factors / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000494:pharmacology; D008929:Mitochondria, Heart / Q000187:drug effects*; D019255:NADPH Oxidases / Q000187:drug effects / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D017382:Reactive Oxygen Species; D020123:Sirolimus / Q000009:adverse effects* / Q000494:pharmacology; D013481:Superoxides / Q000378:metabolism; D014661:Vasoconstriction / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects
D045462:Endothelium-Dependent Relaxing Factors; D007166:Immunosuppressive Agents; D017382:Reactive Oxygen Species; D013481:Superoxides; D009569:Nitric Oxide; D019255:NADPH Oxidases; D020123:Sirolimus